| Outcome Measures: |
Primary: Radiologic liver parameters, Number of participants reported change in liver fat content from baseline, as quantified by fibroscan, up to 24 weeks | Secondary: HbA1c% levels compare with baseline in 6 months, Efficacy, up to 24 weeks|Change in body weight compare with baseline in 6 months, Body Weight, up to 24 weeks|Change in waist circumference compare with baseline in 6 months, Waist Circumference, up to 24 weeks|Fibrosis 4 score levels compare with baseline in 6 months, Fibrosis Scoring \< 1.45 indicates Fibrosis Stage 0-2, 1.45 to 3.25 is deemed indeterminate fibrosis stage, \> 3.25 indicates Fibrosis stage 3-4, up to 24 weeks|Non-Alchoholic Fatty Liver Disease Fibrosis Score levels compare with baseline in 6 months, Non-Alchoholic Fatty Liver Disease Fibrosis Scoring, \< -1.455 indicates Fibrosis Stage 0-2, -1.455 to 0.676 is considered indeterminate fibrosis stage, \> 0.676 indicates Fibrosis Stage 3-4, up to 24 weeks|Frequency of adverse events in 6 months, Safety, up to 24 weeks
|
